Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Immunoassay-Gamma Counters Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | Europe | 350 Pages | No of Tables: 222 | No of Figures: 49

Report Description

Europe Immunoassay-Gamma Counters Market, By Product Type (Automated, Manual/ Semi-Automated), Well (Multi-well, Single-well), Application (Radio Immunoassays, Nuclear Medicine Assays, Others), Disease Condition (Cancer Biomarker, Infectious Diseases, Therapeutic Drug Monitoring, Endocrine Hormones, Allergy, Neonatal Screening, Cardiac Markers, Auto Immune Disease, Others), Purchase Mode (Out-right Purchase, Rental Purchase), End User (Laboratory, Hospitals, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Blood banks, Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2028.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Europe Immunoassay-Gamma Counters Market

Europe immunoassay-gamma counters market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.0% in the forecast period of 2021 to 2028 and is expected to reach USD 25.51 million by 2028. Increasing prevalence of chronic diseases, and increasing adoption of nuclear medicine are the major drivers which propelled the demand of the market in the forecast period.

An immunoassay is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody or an antigen. The biochemical test is carried out through a device known as “Gamma Counter”. A gamma counter is an instrument to measure gamma radiation emitted by a radionuclide. Unlike survey meters, gamma counters are designed to measure small samples of radioactive material, typically with automated measurement and movement of multiple samples. Growing research and development expenditures, increasing healthcare expenditure, and rising patient awareness towards chronic disease treatment is expected to provide a lucrative growth opportunity for the market. However, high cost of gamma counters, and risk of gamma radiation are the factors expected to restraint the market growth in the forecast period.

The demand for the immunoassay-gamma counters market has been increased in both developed and developing countries, and the reason behind this is an increase in global healthcare expenditure. The immunoassay-gamma counters market is growing due to increased approval of advanced technological products and increased government support. The market will grow in the forecasted period with an increase in strategic initiatives by market players.

The immunoassay-gamma counters market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Europe Immunoassay-Gamma Counters Market Scope and Market Size   

Immunoassay gamma counters market is segmented on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of product type, Europe immunoassay-gamma counters market is segmented into automated, manual/semi-automated. In 2021 automated segment is expected to dominate the market due to reduced factory lead times, and ability to be more competitive.
  • On the basis of well, Europe immunoassay-gamma counters market is segmented into multi-well, single-well. In 2021, the multi-well segment is expected to dominate the market because of accurate measurements, and ability to produce higher spectra levels in short period of time.
  • On the basis of application, Europe immunoassay-gamma counters market is segmented into radio immunoassays, nuclear medicine assays, others. In 2021, radio immunoassays is expected to dominate the market due to high specificity, and sensitivity.
  • On the basis of disease condition, Europe immunoassay-gamma counters market is segmented into cancer biomarker, infectious diseases, therapeutic drug monitoring, endocrine hormones, allergy, neonatal screening, cardiac markers, auto immune disease, others. In 2021, the cancer biomarkers segment is expected to dominate the market due to study of disease mechanisms, and well- characterization
  • On the basis of purchase mode, the Europe immunoassay-gamma counters market is segmented into out-right purchase, rental purchase.  In 2021, the out-right purchase segment is expected to dominate the market due to improved internal effectiveness, and innovation
  • On the basis of end user, the Europe immunoassay-gamma counters market is segmented into Laboratory, hospitals, research & academic institutes, pharmaceutical & biotechnology companies, blood banks, others. In 2021, the laboratory segment is expected to dominate the market due to repeatability, and objectivity along with real time monitoring
  • On the basis of distribution channel, the Europe immunoassay-gamma counters market is segmented into direct sales and third party distributors. In 2021, direct tender segment is expected to dominate the market because of re-engagement, cost savings, and independent talent

Immunoassay-Gamma Counters Market Country Level Analysis

The immunoassay-gamma counters market is analyzed and market size information is provided on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel

The countries covered in the immunoassay-gamma counters market report are France, U.K., Italy, Germany, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.

Radio immunoassay segment in Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 due to high specificity, and sensitivity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Product approvals and novelty in diagnosis procedures are boosting the market growth of immunoassay-gamma counters. 

Immunoassay gamma counters market also provides you with detailed market analysis for every country growth in bacteriophage therapy industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Bacteriophages Therapy Market Share Analysis

Immunoassay gamma counters market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to immunoassay-gamma counters market.

The major companies operating in the Europe immunoassay-gamma counters market are Hidex Oy, Perkin Elmer Inc, Berthold Technologies GmbH & Co. KG, ENERSYS Co. Ltd, Shinjin Medics Inc, LabLogic Systems Ltd, among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the immunoassay-gamma counters market.

For instance,

  • In July 2021, PerkinElmer Inc. announced that the company is further looking to expand their footprints in India by relying on innovative products. The new products will be launched in various streams such as science, pharma, and food testing. This has helped the company to expand its global presence.
  •  In November 2020, Berthold Technologies GmbH & C0.KG announced that the partial lockdown was ordered to reduce infection rate. However, the company assured to the customers about the reliable delivery as they keep up the production during this time, following the proper guidelines by the government. This helps the company to maintain the demand and generate revenue during the pandemic.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the immunoassay-gamma counters market which also provides the benefit for organization to improve their offering for immunoassay-gamma counters.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTES FIVE FORCES

5 REGULATORY GUIDELINES FOR IMMUNOASSAY-GAMMA COUNTERS

5.1 U.S. REGULATORY GUIDELINES FOR IMMUNOASSAYS-GAMMA COUNTERS

5.2 EUROPE REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

5.3 JAPAN REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

5.4 CHINA REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN PREVALENCE OF CHRONIC DISEASES

6.1.2 PRODUCT APPROVAL

6.1.3 INCREASE IN ADOPTION OF NUCLEAR MEDICINE

6.1.4 NOVELTY IN DIAGNOSIS PROCEDURES

6.1.5 UPGRADING GAMMA TECHNOLOGY

6.2 RESTRAINTS

6.2.1 HIGH COST OF GAMMA COUNTER

6.2.2 RISK OF GAMMA RADIATION

6.2.3 STRINGENT REGULATION OF CLINICAL USE OF GAMMA COUNTER

6.2.4 PRODUCT RECALL

6.3 OPPORTUNITIES

6.3.1 GROWING RESEARCH AND DEVELOPMENT EXPENDITURE

6.3.2 INCREASE IN HEALTHCARE EXPENDITURE

6.3.3 RISE IN PATIENTS AWARENESS TOWARDS CHRONIC DISEASE TREATMENT

6.4 CHALLENGES

6.4.1 CHALLENGES IN USING GAMMA COUNTER

6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7 IMPACT OF COVID-19 ON EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET

7.1 IMPACT ON THE PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVES BY MANUFACTURERS

7.5 CONCLUSION

8 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 AUTOMATED

8.2.1 RADIOIMMUNOASSAYS

8.2.1.1 RIA

8.2.1.2 IRMA

8.2.2 NUCLEAR MEDICINE ASSAYS

8.2.2.1 GFR (Glomerular FILTRATION RATE)

8.2.2.2 Gamma glutamyl transferase (ggt)

8.2.2.3 red cell mass and plasma volume test

8.2.2.4 THE SCHILLING TEST

8.2.2.5 others

8.2.3 OTHERS

8.3 MANUAL/SEMI-AUTOMATED

8.3.1 RADIOIMMUNOASSAYS

8.3.1.1 RIA

8.3.1.2 IRMA

8.3.2 NUCLEAR MEDICINE ASSAYS

8.3.2.1 GFR (Glomerular FILTRATION RATE)

8.3.2.2 Gamma glutamyl transferase (ggt)

8.3.2.3 red cell mass and plasma volume test

8.3.2.4 THE SCHILLING TEST

8.3.2.5 others

8.3.3 OTHERS

9 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL

9.1 OVERVIEW

9.2 MULTI-WELL

9.3 SINGLE-WELL

10 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 RADIO IMMUNOASSAYS

10.2.1 RIA

10.2.2 IRMA

10.3 NUCLEAR MEDICINE ASSAY

10.3.1 GFR (GLOMERULAR FILTRATION RATE)

10.3.2 GAMMA-GLUTAMYL TRANSFERASE

10.3.3 RED CELL MASS AND PLASMA VOLUME TEST

10.3.4 THE SCHILLING TEST

10.3.5 OTHERS

10.4 OTHERS

11 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION

11.1 OVERVIEW

11.2 CANCER BIOMARKERS

11.2.1 CARBOHYDRATE ANTIGEN 125 (CA125)

11.2.2 CARBOHYDRATE ANTIGEN 19-9

11.2.3 CARCINO EMBRYONIC ANTIGEN

11.2.4 ALPHA-FETOPROTEIN

11.2.5 OTHERS

11.3 INFECTIOUS DISEASES

11.4 THERAPEUTIC DRUG MONITORING

11.5 ENDOCRINE HORMONES

11.6 ALLERGY

11.7 NEONATAL SCREENING

11.8 CARDIAC MARKERS

11.9 AUTOIMMUNE DISEASE

11.1 OTHERS

12 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE

12.1 OVERVIEW

12.2 OUTRIGHT PURCHASE

12.3 RENTAL PURCHASE

13 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 THIRD PARTY DISTRIBUTORS

14 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 LABORATORY

14.4 BLOOD BANKS

14.5 RESEARCH AND ACADEMIC INSTITUTES

14.6 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

14.7 OTHERS

15 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY GEOGRAPHY

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 NETHERLANDS

15.1.7 RUSSIA

15.1.8 SWITZERLAND

15.1.9 BELGIUM

15.1.10 TURKEY

15.1.11 REST OF EUROPE

16 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PERKINELMER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 BRETHOLD TECHNOLOGIES GMBH & CO.KG

18.2.1 COMPANY SNAPSHOT

18.2.2 COMPANY SHARE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENTS

18.3 LABLOGIC SYSTEMS LTD.

18.3.1 COMPANY SNAPSHOT

18.3.2 COMPANY SHARE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 SHIN JIN MEDICS INC.

18.4.1 COMPANY SNAPSHOT

18.4.2 COMPANY SHARE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 HIDEX OY

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENTS

18.6 LABORATORY TECHNOLOGIES. INC.

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 ENERSYS, CO.LTD.

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 MIRION TECHNOLOGIES (CAPINTEC),INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS

TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 3 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 4 EUROPE AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 5 EUROPE AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 6 EUROPE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 7 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 8 EUROPE MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 9 EUROPE MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 10 EUROPE RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 11 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 12 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 13 EUROPE MULTI-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 14 EUROPE SINGLE-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 15 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 16 EUROPE RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 17 EUROPE RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 18 EUROPE NUCLEAR MEDICINE ASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 19 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 20 EUROPE OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 21 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 22 EUROPE CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 23 EUROPE CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 24 EUROPE INFECTIOUS DISEASES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 25 EUROPE THERAPEUTIC DRUG MONITORING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 26 EUROPE ENDOCRINE HORMONES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 27 EUROPE ALLERGY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 28 EUROPE NEONATAL SCREENING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 29 EUROPE CARDIAC MAKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 30 EUROPE AUTO IMMUNE DISEASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 31 EUROPE OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 32 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 33 EUROPE OUTRIGHT PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 34 EUROPE RENTAL PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 35 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 36 EUROPE DIRECT TENDER IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 37 EUROPE THIRD PARTY DISTRIBUTORS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 38 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 39 EUROPE HOSPITALS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 40 EUROPE LABORATORY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 41 EUROPE BLOOD BANKS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 20152028 (USD MILLION)

TABLE 42 EUROPE RESEARCH AND ACADEMIC INSTITUTES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 43 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 44 OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 45 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY COUNTRY, 2015-2028 (USD MILLION)

TABLE 46 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 47 EUROPE AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 48 EUROPE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 49 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 50 EUROPE MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 51 EUROPE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 52 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 53 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 54 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 55 EUROPE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 56 EUROPE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 57 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 58 EUROPE CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 59 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 60 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 61 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 62 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 63 GERMANY AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 64 GERMANY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 65 GERMANY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 66 GERMANY MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 67 GERMANY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 68 GERMANY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 69 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 70 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 71 GERMANY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 72 GERMANY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 73 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 74 GERMANY CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 75 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 76 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 77 GERMANY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 78 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 79 U.K. AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 80 U.K. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 81 U.K. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 82 U.K. MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 83 U.K. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 84 U.K. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 85 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 86 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 87 U.K. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 88 U.K. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 89 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 90 U.K. CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 91 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 92 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 93 U.K. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 94 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 95 FRANCE AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 96 FRANCE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 97 FRANCE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 98 FRANCE MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 99 FRANCE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 100 FRANCE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 101 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 102 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 103 FRANCE RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 104 FRANCE NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 105 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 106 FRANCE CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 107 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 108 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 109 FRANCE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 110 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 111 ITALY AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 112 ITALY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 113 ITALY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 114 ITALY MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 115 ITALY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 116 ITALY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 117 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 118 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 119 ITALY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 120 ITALY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 121 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 122 ITALY CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 123 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 124 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 125 ITALY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 126 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 127 SPAIN AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 128 SPAIN RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 129 SPAIN NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 130 SPAIN MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 131 SPAIN RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 132 SPAIN NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 133 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 134 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 135 SPAIN RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 136 SPAIN NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 137 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 138 SPAIN CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 139 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 140 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 141 SPAIN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 142 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 143 NETHERLANDS AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 144 NETHERLANDS RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 145 NETHERLANDS NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 146 NETHERLANDS MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 147 NETHERLANDS RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 148 NETHERLANDS NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 149 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 150 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 151 NETHERLANDS RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 152 NETHERLANDS NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 153 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 154 NETHERLANDS CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 155 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 156 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 157 NETHERLANDS IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 158 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 159 RUSSIA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 160 RUSSIA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 161 RUSSIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 162 RUSSIA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 163 RUSSIA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 164 RUSSIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 165 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 166 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 167 RUSSIA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 168 RUSSIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 169 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 170 RUSSIA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 171 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 172 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 173 RUSSIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 174 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 175 SWITZERLAND AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 176 SWITZERLAND RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 177 SWITZERLAND NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 178 SWITZERLAND MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 179 SWITZERLAND RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 180 SWITZERLAND NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 181 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 182 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 183 SWITZERLAND RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 184 SWITZERLAND NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 185 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 186 SWITZERLAND CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 187 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 188 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 189 SWITZERLAND IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 190 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 191 BELGIUM AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 192 BELGIUM RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 193 BELGIUM NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 194 BELGIUM MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 195 BELGIUM RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 196 BELGIUM NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 197 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 198 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 199 BELGIUM RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 200 BELGIUM NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 201 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 202 BELGIUM CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 203 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 204 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 205 BELGIUM IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 206 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 207 TURKEY AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 208 TURKEY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 209 TURKEY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 210 TURKEY MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 211 TURKEY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 212 TURKEY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 213 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 214 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 215 TURKEY RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 216 TURKEY NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 217 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 218 TURKEY CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 219 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 220 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 221 TURKEY IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 222 REST OF EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

List of Figure

FIGURE 1 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 2 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID

FIGURE 10 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET

FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS

FIGURE 16 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020

FIGURE 17 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)

FIGURE 18 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 19 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020

FIGURE 21 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)

FIGURE 22 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)

FIGURE 23 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE

FIGURE 24 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020

FIGURE 25 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 26 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)

FIGURE 27 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 28 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020

FIGURE 29 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)

FIGURE 30 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)

FIGURE 31 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE

FIGURE 32 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020

FIGURE 33 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)

FIGURE 34 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)

FIGURE 35 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE

FIGURE 36 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020

FIGURE 37 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 38 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 39 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020

FIGURE 41 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)

FIGURE 43 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : SNAPSHOT (2020)

FIGURE 45 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2020)

FIGURE 46 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2021 &2028)

FIGURE 47 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2020 & 2028)

FIGURE 48 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE (2021-2028)

FIGURE 49 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 2 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID

FIGURE 10 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET

FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS

FIGURE 16 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020

FIGURE 17 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)

FIGURE 18 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 19 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020

FIGURE 21 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)

FIGURE 22 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)

FIGURE 23 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE

FIGURE 24 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020

FIGURE 25 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 26 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)

FIGURE 27 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 28 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020

FIGURE 29 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)

FIGURE 30 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)

FIGURE 31 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE

FIGURE 32 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020

FIGURE 33 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)

FIGURE 34 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)

FIGURE 35 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE

FIGURE 36 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020

FIGURE 37 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 38 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 39 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020

FIGURE 41 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)

FIGURE 43 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : SNAPSHOT (2020)

FIGURE 45 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2020)

FIGURE 46 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2021 &2028)

FIGURE 47 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY COUNTRY (2020 & 2028)

FIGURE 48 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE (2021-2028)

FIGURE 49 EUROPE IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19